Fenebrutinib is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase III program in Relapsing Multiple Sclerosis (RMS). According to Globaldata, it is involved in 20 clinical trials, of which 14 were completed, 4 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Fenebrutinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Fenebrutinib is expected to reach an annual total of $505 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fenebrutinib Overview
Fenebrutinib (GDC-0853, RG-7845) is under development for the treatment of B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, indolent lymphoma, follicular lymphoma, relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). It is administered orally. The drug candidate is a second generation Bruton's tyrosine kinase (BTK) inhibitor. It is a new molecular entity. It was also under development for the treatment of systemic lupus erythematosus, rheumatoid arthritis and chronic spontaneous urticaria.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of Fenebrutinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.